Withdrawal of Statins in Patients With Acute Coronary Syndromes
2003; Lippincott Williams & Wilkins; Volume: 107; Issue: 3 Linguagem: Inglês
10.1161/01.cir.0000050552.32300.93
ISSN1524-4539
AutoresChristopher Heeschen, Christian W. Hamm, Ulrich Laufs, Michael Böhm, Steven Snapinn, Harvey D. White,
Tópico(s)Antiplatelet Therapy and Cardiovascular Diseases
ResumoHomeCirculationVol. 107, No. 3Withdrawal of Statins in Patients With Acute Coronary Syndromes Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBWithdrawal of Statins in Patients With Acute Coronary Syndromes Christopher Heeschen, MD Christian W. Hamm, MD Ulrich Laufs, MD and Michael Böhm, MD Steven Snapinn, PhD Harvey D. White, DSc Christopher HeeschenChristopher Heeschen University Hospital Frankfurt, Frankfurt, Germany Christian W. HammChristian W. Hamm Kerckhoff Heart Center, Bad Nauheim, Germany Ulrich LaufsUlrich Laufs University Hospital Homburg (Saar), Germany and Michael BöhmMichael Böhm University Hospital Homburg (Saar), Germany Steven SnapinnSteven Snapinn Merck Research Laboratories, West Point, Pa Harvey D. WhiteHarvey D. White Green Lane Hospital, Auckland, New Zealand Originally published28 Jan 2003https://doi.org/10.1161/01.CIR.0000050552.32300.93Circulation. 2003;107:e27To the Editor:In a recent article,1 we reported that pretreatment with statins before onset of symptoms in patients with acute coronary syndromes is associated with significantly improved clinical outcomes, and that discontinuation of statin therapy after onset of symptoms completely abrogates the beneficial effect of statin therapy. We have reevaluated our data and found inaccuracies in our analysis such that we can no longer support these original conclusions.In reevaluating our data, we discovered that approximately one-third of the study population had missing data for troponin T at baseline and were excluded from the multivariate model we used to adjust for possible confounding factors. The exclusion of these patients had a large impact on the results. When we repeated the analysis using all patients irrespective of troponin T status, the effects trended in the same direction but were considerably more modest. Patients receiving statin therapy had a non-significantly lower rate of myocardial infarction and/or death at 30-day follow-up compared with patients not receiving statins (adjusted hazard ratio, 0.70 [95% confidence interval, 0.41 to 1.19]; P=0.19). Risk tended to be higher in patients who discontinued statin therapy relative than in those who continued to receive statins (adjusted hazard ratio, 2.22 [95% confidence interval, 0.90 to 5.49]; P=0.08), and there was little difference relative to patients who never received statins (adjusted hazard ratio, 1.50 [95% confidence interval, 0.70 to 3.19]; P=0.30).We also recalculated the crude rates. For example, the crude rates of myocardial infarction or death at 30 days were 6.7% among patients who did not receive statins, 4.2% among patients who continued statins, and 9.4% among patients who discontinued statins. Although the rate was highest among patients who discontinued statin use, the comparisons among all 3 groups (P=0.10) and between the continued and discontinued groups (P=0.060) were not statistically significant. The corresponding rates of myocardial infarction/death at 7 days were 3.8%, 2.9%, and 8.2%, respectively (P=0.082 among all 3 groups and P=0.031 between the continued and discontinued groups).Although the direction of the trend is maintained in this reanalysis, there is insufficient evidence to support the original conclusions. These data remain interesting, and we reiterate that unplanned post hoc analyses are useful in generating hypotheses that should be rigorously tested in randomized controlled trials before being accepted and adopted into clinical practice. We apologize for any confusion that may have arisen from the original publication. References 1 Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002; 105: 1446–1452.LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Wu X, Liu X, Liu T, Tian W and Sun Y (2021) Effects of different statins application methods on plaques in patients with coronary atherosclerosis, World Journal of Clinical Cases, 10.12998/wjcc.v9.i4.812, 9:4, (812-821), Online publication date: 6-Feb-2021. Jeong H, Lee S, Kim S and Kim J (2020) Long-Term Benefit and Withdrawal Effect of Statins After Percutaneous Coronary Intervention: A Nationwide Population-Based Cohort Study, Patient Preference and Adherence, 10.2147/PPA.S245324, Volume 14, (717-724) Mermis J and Simpson S (2014) Counterpoint: Should Patients Receiving Statins Prior to ICU Admission Be Continued on Statin Therapy? No, Chest, 10.1378/chest.14-2225, 146:6, (1433-1435), Online publication date: 1-Dec-2014. Oddsson S, Sigurdsson M, Helgadottir S, Sigurjonsson H, Viktorsson S, Arnorsson T, Thorgeirsson G and Gudbjartsson T (2012) Lower mortality following coronary arterial revascularization in patients taking statins, Scandinavian Cardiovascular Journal, 10.3109/14017431.2012.719633, 46:6, (353-358), Online publication date: 1-Dec-2012. Reidenberg M (2011) Drug Discontinuation Effects Are Part of the Pharmacology of a Drug, Journal of Pharmacology and Experimental Therapeutics, 10.1124/jpet.111.183285, 339:2, (324-328), Online publication date: 1-Nov-2011. Pineda A and Cubeddu L (2010) Statin Rebound or Withdrawal Syndrome: Does It Exist?, Current Atherosclerosis Reports, 10.1007/s11883-010-0148-x, 13:1, (23-30), Online publication date: 1-Feb-2011. Teixeira M (2010) Statins withdrawal, vascular complications, rebound effect and similitude, Homeopathy, 10.1016/j.homp.2010.01.001, 99:4, (255-262), Online publication date: 1-Oct-2010. Chen H, Ren J, Xing Y, Zhang W, Liu X, Wu P, Wang R and Luo Y (2009) Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: A dose–response effect dependent on endothelial nitric oxide synthase, International Journal of Cardiology, 10.1016/j.ijcard.2007.10.044, 131:3, (313-320), Online publication date: 1-Jan-2009. Schwartz G (2009) Special Patient Populations: Acute Coronary Syndromes Clinical Lipidology, 10.1016/B978-141605469-6.50043-3, (473-485), . Cevik C, Otahbachi M, Nugent K, Warangkana C and Meyerrose G (2008) Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization, Journal of Cardiovascular Medicine, 10.2459/JCM.0b013e328316912f, 9:12, (1274-1278), Online publication date: 1-Dec-2008. Tziomalos K, Athyros V and Mikhailidis D (2008) Statin discontinuation: an underestimated risk?, Current Medical Research and Opinion, 10.1185/03007990802469102, 24:11, (3059-3062), Online publication date: 1-Nov-2008. Westphal S, Abletshauser C and Luley C (2008) Fluvastatin Treatment and Withdrawal: Effects on Endothelial Function, Angiology, 10.1177/0003319708316005, 59:5, (613-618), Online publication date: 1-Oct-2008. Poldermans D, Hoeks S and Feringa H (2008) Pre-Operative Risk Assessment and Risk Reduction Before Surgery, Journal of the American College of Cardiology, 10.1016/j.jacc.2008.03.005, 51:20, (1913-1924), Online publication date: 1-May-2008. Howard-Alpe G, Foëx P and Biccard B (2008) Cardiovascular protection by anti-inflammatory statin therapy, Best Practice & Research Clinical Anaesthesiology, 10.1016/j.bpa.2007.08.001, 22:1, (111-133), Online publication date: 1-Mar-2008. Biccard B (2007) A peri-operative statin update for non-cardiac surgery. Part I: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (non-surgical) patients, Anaesthesia, 10.1111/j.1365-2044.2007.05264.x, 63:1, (52-64) Levin A (2014) Till death us do part? Postoperative statin discontinuation , Southern African Journal of Anaesthesia and Analgesia, 10.1080/22201173.2008.10872514, 14:1, (7-12), Online publication date: 1-Jan-2008. Castejon A, Zollner E, Tristano A and Cubeddu L (2007) Upregulation of Angiotensin II-AT1 Receptors During Statin Withdrawal in Vascular Smooth Muscle Cells, Journal of Cardiovascular Pharmacology, 10.1097/FJC.0b013e318157c0b2, 50:6, (708-711), Online publication date: 1-Dec-2007. Tanvetyanon T (2019) Letters to the Editor, Journal of Palliative Care, 10.1177/082585970702300311, 23:3, (189-189), Online publication date: 1-Sep-2007. Levin A and Coetzee A (2014) Statins and perioperative myocardial infarction. Mechanisms of action, Southern African Journal of Anaesthesia and Analgesia, 10.1080/22201173.2007.10872496, 13:4, (33-43), Online publication date: 1-Jul-2007. Ding D, Shyu W, Lin S and Li H (2017) The Role of Endothelial Progenitor Cells in Ischemic Cerebral and Heart Diseases, Cell Transplantation, 10.3727/000000007783464777, 16:3, (273-284), Online publication date: 1-Mar-2007. Endres M and Laufs U (2006) Discontinuation of Statin Treatment in Stroke Patients, Stroke, 37:10, (2640-2643), Online publication date: 1-Oct-2006. Cubeddu L and Seamon M (2006) Statin Withdrawal: Clinical Implications and Molecular Mechanisms, Pharmacotherapy, 10.1592/phco.26.9.1288, 26:9, (1288-1296), Online publication date: 1-Sep-2006. Akhtar S (2006) Ischemic Heart Disease, Anesthesiology Clinics of North America, 10.1016/j.atc.2006.04.002, 24:3, (461-485), Online publication date: 1-Sep-2006. Biccard B, Sear J and Foëx P (2005) Statin therapy: a potentially useful peri-operative intervention in patients with cardiovascular disease, Anaesthesia, 10.1111/j.1365-2044.2005.04405.x, 60:11, (1106-1114), Online publication date: 1-Nov-2005. Biccard B, Sear J and Foëx P (2005) The pharmaco-economics of peri-operative statin therapy, Anaesthesia, 10.1111/j.1365-2044.2005.04371.x, 60:11, (1059-1063), Online publication date: 1-Nov-2005. Endres M (2005) Statins and Stroke, Journal of Cerebral Blood Flow & Metabolism, 10.1038/sj.jcbfm.9600116, 25:9, (1093-1110), Online publication date: 1-Sep-2005. Sukkar M, Issa R, Xie S, Oltmanns U, Newton R and Chung K (2004) Fractalkine/CX 3 CL1 production by human airway smooth muscle cells: induction by IFN-γ and TNF-α and regulation by TGF-β and corticosteroids , American Journal of Physiology-Lung Cellular and Molecular Physiology, 10.1152/ajplung.00014.2004, 287:6, (L1230-L1240), Online publication date: 1-Dec-2004. Endres M and Laufs U (2004) Effects of Statins on Endothelium and Signaling Mechanisms, Stroke, 35:11_suppl_1, (2708-2711), Online publication date: 1-Nov-2004.Stone N (2004) Stopping Statins, Circulation, 110:16, (2280-2282), Online publication date: 19-Oct-2004.McGowan M (2004) There Is No Evidence for an Increase in Acute Coronary Syndromes After Short-Term Abrupt Discontinuation of Statins in Stable Cardiac Patients, Circulation, 110:16, (2333-2335), Online publication date: 19-Oct-2004. Walter D, Zeiher A and Dimmeler S (2004) Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells, Coronary Artery Disease, 10.1097/01.mca.0000131572.14521.8a, 15:5, (235-242), Online publication date: 1-Aug-2004. Walter D, Asahara T and Losordo D (2004) Effects of Statins on Endothelial Progenitor Cells: Mobilization, Differentiation, and Contribution to Adult Neovascularization Statins, 10.1016/B978-0-7216-0380-3.50022-3, (257-269), . Davignon J (2004) The cardioprotective effects of statins, Current Atherosclerosis Reports, 10.1007/s11883-004-0113-7, 6:1, (27-35), Online publication date: 1-Jan-2004. Gottlieb R (2003) Cytochrome P450: major player in reperfusion injury, Archives of Biochemistry and Biophysics, 10.1016/j.abb.2003.07.004, 420:2, (262-267), Online publication date: 1-Dec-2003. January 28, 2003Vol 107, Issue 3 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000050552.32300.93PMID: 12551886 Originally publishedJanuary 28, 2003 PDF download Advertisement
Referência(s)